Top Story

Despite ‘incremental’ progress, long-term survival rates ‘have not budged’ in glioblastoma

Despite ‘incremental’ progress, long-term survival rates ‘have not budged’ in glioblastoma
July 8, 2019
FDA News

FDA approves Zirabev, biosimilar to Avastin

June 28, 2019
The FDA approved bevacizumab-bvzr for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell…
In the Journals

FDA-approved cancer drugs take more than 6 years to reach children

June 25, 2019
FDA-approved oncology agents took a median 6.5 years to proceed from first-in-human to first-in-child clinical trials, according to research published in European

Artificial neural network shows potential for assessment of glioblastoma treatment response

June 25, 2019
Researchers from Heidelberg University Hospital and the German Cancer Research Center have developed a novel technology that involves machine learning methods trained on…
More Headlines »

Ace the Case: A 54-year-old Man With 2 Weeks of Progressive Shortness of Breath

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the management of a 54-year-old man with 2 weeks of…
More »
Meeting News

VIDEO: Cancer vaccine targets glioblastoma

June 11, 2018
More »

Innovations in Sickle Cell Disease: How the Latest Advances May Impact Clinical Decision Making – Rapid Response From Amsterdam

This activity is supported by an educational grant from Global Blood Therapeutics.

Sickle cell disease (SCD) is an inherited molecular condition whose clinical severity has extreme phenotypic…
More »